Get the Stockscreener App
2.74
6.48%
-0.19
After Hours:
2.77
0.03
+1.09%
Soligenix Inc stock is traded at $2.74, with a volume of 7.74M.
It is down -6.48% in the last 24 hours and up +94.33% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$2.93
Open:
$2.66
24h Volume:
7.74M
Relative Volume:
1.16
Market Cap:
$8.94M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.3624
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+107.58%
1M Performance:
+94.33%
6M Performance:
+17.60%
1Y Performance:
-37.59%
1-Day Range:
$2.39
$2.91
1-Week Range:
$1.18
$5.38
52-Week Range:
$1.09
$5.40
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.74 | 9.56M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Should I hold or sell Soligenix Inc. stock in 2025Market Forecast Data Feed From AI Tools - jammulinksnews.com
Soligenix Completes Promising Study on Dusquetide for Behcet’s Disease - TipRanks
How does Soligenix Inc. compare to its industry peersEarnings Report Watchlist Backed By Experts - jammulinksnews.com
Soligenix Stock Skyrockets: Should You Invest? - timothysykes.com
Why Did Soligenix Plunge 12.97% Despite Positive Trial Results? - AInvest
Soligenix’s $1.17B Volume Surge Propels 134% Rally, Ranked 108th in Market Activity - AInvest
Soligenix’s Phase 3 Study on HyBryte for CTCL: Key Insights for Investors - MSN
Soligenix Completes Phase 2a Study for SGX945 - TipRanks
Soligenix Reports Positive Phase 2a Data in Behçet’s Disease - Dermatology Times
SNGX.O (Soligenix) Surges 144%: A Deep Dive into the Drivers Behind the Intraday Move - AInvest
SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease… - Zacks Small Cap Research
This Stock Soared after Successful Treatment of Rare Disease - FXLeaders
What markets is FATBB expanding into Is Soligenix Inc. stock a good long term investment optionWealth Building Planner With Proven Results - jammulinksnews.com
Soligenix shares surge 106.40% intraday after completing Phase 2a proof of concept study for SGX945 in Behcet's Disease. - AInvest
Soligenix Stock Soars: Is A Rebound Imminent? - StocksToTrade
Why Is Soligenix Stock (SNGX) Up 50% Today? - TipRanks
Soligenix Stock Skyrockets: What Comes Next? - timothysykes.com
Is Soligenix Inc. a growth stock or a value stockTop Growth Ideas For 2025 - jammulinksnews.com
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance
Soligenix reports positive results from SGX945 Behçet’s trial - Investing.com
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PR Newswire
What institutional investors are buying Soligenix Inc. stockExpert Picks Outlook From AI Tools - jammulinksnews.com
Long term hold vs stop loss in Soligenix Inc.AI Powered Stock Trend Prediction Model - Newser
What momentum shifts mean for Soligenix Inc.Trade Safety Report with Pattern Insights - Newser
Can technical indicators confirm Soligenix Inc.’s reversalTechnical Confirmation System with Signal Alerts - Newser
What institutional flow reveals about Soligenix Inc.Long-Term Trend Tracking and Signal Summary - Newser
Why Soligenix Inc. stock attracts strong analyst attentionMulti-Year Investment Performance Summary Report - Newser
Multi factor analysis applied to Soligenix Inc.ROI Focused Watchlist with Trade Confidence - Newser
What makes Soligenix Inc. stock price move sharplyHistorical Stock Summary and ROI Review - Newser
Soligenix Inc. Stock Support and Resistance Levels You Should KnowAI Based High Gain Watchlist Scanner Shared - metal.it
Real time social sentiment graph for Soligenix Inc.High Yield Watchlist with Filtered Picks - Newser
Order Flow Trends Show Accumulation in Soligenix Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
How did Soligenix's revenue and expenses trend in Q4 2024? - AInvest
Published on: 2025-07-29 03:42:31 - metal.it
Why is Soligenix Inc. stock attracting strong analyst attentionDaily Trading Signals That Work - jammulinksnews.com
What is the dividend policy of Soligenix Inc. stockCapitalize on market momentum for profits - jammulinksnews.com
What is Soligenix Inc. company’s growth strategyAchieve breakthrough investment performance - jammulinksnews.com
How volatile is Soligenix Inc. stock compared to the marketTake advantage of unprecedented market momentum - jammulinksnews.com
What is the risk reward ratio of investing in Soligenix Inc. stockIdentify safe investments with exceptional yields - jammulinksnews.com
Top Risks to Consider Before Buying Soligenix Inc. StockStable Stocks With High Yield - Newser
What catalysts could drive Soligenix Inc. stock higher in 2025Capitalize on market trends with confidence - jammulinksnews.com
How Soligenix Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):